Skip to main content
SpringerLink
Log in

Lower costs with everolimus-based treatment in HR+/HER2− MBC

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. This study was funded by Novartis.

Reference

  • Hao Y, et al. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy. Advances in Therapy : 23 May 2016. Available from: URL: http://dx.doi.org/10.1007/s12325-016-0328-3

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lower costs with everolimus-based treatment in HR+/HER2− MBC. PharmacoEcon Outcomes News 755, 29 (2016). https://doi.org/10.1007/s40274-016-3136-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3136-8

Search

Navigation